Opinion

Video

Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients

Author(s):

Preet M. Chaudhary, MD, PhDNoah Merin, MD, PhD

A brief review of the key efficacy data for two treatment options, Ibrutinib and Belumosudil, in patients with chronic GvHD.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Related Content